Monday, December 23, 2024
HomeTagsInhibitor ATG-037

Inhibitor ATG-037

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

Antengene Corporation Limited, a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, announced...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics